Apatinib: all 412 studies that test it
Page 1 of 5. Open to participants first (94), then studies with results posted, then the rest; newest registration first within each.
- Retlirafusp Alfa Combined With Zeprumetostat, Apatinib, and Chemotherapy as First-Line Treatment for Metastatic GC/GEJCNot yet recruitingNCT07874425Phase 2
- GnP Combined With SHR-1701 and Apatinib as First-Line Treatment for Locally Advanced or Metastatic PDACNot yet recruitingNCT07802184Phase 1/2
- A Prospective, Single-Arm, Open-Label Clinical Study of the Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy Combined With Targeted Therapy and a PD-1 Inhibitor in Patients With Postoperative Hepatocellular Carcinoma and Microvascular InvasionNot yet recruitingNCT07790419Phase 4
- Retlirafusp Alfa Plus Apatinib and Chemotherapy as Second-Line Treatment for Pancreatic CancerNot yet recruitingNCT07773363Phase 2
- SHR-1701 Plus Apatinib for Second-Line Treatment in Targeted-Immune Pretreated Advanced Hepatocellular CarcinomaNot yet recruitingNCT07749859Phase 2
- Precision Medicine for Immunotherapy-Resistant Advanced Esophageal CancerNot yet recruitingNCT07653451Phase 2/3
- A Multicenter, Randomized, Open-label, Controlled Study of HAIC Combined With Camrelizumab and Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma With High-risk Recurrence FactorsNot yet recruitingNCT07618546Not applicable
- Retlirafusp Alfa Combined With Apatinib and Nab-Paclitaxel as Second-line Treatment for Gastric or Gastroesophageal Junction CancerNot yet recruitingNCT07610629Phase 2
- Alternating HAIC and Systemic Chemotherapy With or Without Adebrelimab and Apatinib for Unresectable Biliary Tract CancerRecruitingNCT07569679Phase 2
- SHR-1701 With or Without Apatinib in Combination With Chemotherapy as Neoadjuvant Therapy for Gastric CancerRecruitingNCT07464756Phase 2
- Exploration of Treatment Strategies After Concurrent Chemoradiotherapy for LS-SCLC Guided by MRDNot yet recruitingNCT07357532Phase 2
- Adebrelimab Plus Apatinib Combined With SOX Regimen as Conversion Therapy for Gastric CancerRecruitingNCT07353684Phase 2
- A Study of Yttrium [90Y] Microsphere Injection in Combination With Targeted Immunotherapy in the Treatment of HCCRecruitingNCT07334483Phase 2
- FAD Subtype-Guided Combination Therapy for Unresectable Hepatocellular CarcinomaNot yet recruitingNCT07314372Phase 2
- Clinical Efficacy of Adebrelimab With or Without Apatinib Mesilate and SOX Neoadjuvant Therapy in Locally Advanced Gastric CancerNot yet recruitingNCT07314203Phase 3
- SHR-1701 + Rivoceranib (± SHR-2554) in Advanced GC After First-Line Immunotherapy FailureRecruitingNCT07311408Phase 2
- PDL1/TGFβ In Combination With SHR2554 or Apatinib And Chemotherapy For First - Line Treatment Of Gastric CancerRecruitingNCT07294664Phase 2
- Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal MelanomaNot yet recruitingNCT07236528Phase 2
- Adebrelimab + Apatinib in Advanced HCC Post-Systemic TherapyNot yet recruitingNCT07192848Phase 2
- HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)RecruitingNCT07105748Phase 2
- A Single-arm, Multicenter, Prospective Clinical Study of Adebrelimab Combined With Apatinib Neoadjuvant Therapy for Resectable Non-small Cell Lung CancerNot yet recruitingNCT07031154Phase 2
- Individualized Comprehensive Treatment for Advanced Hepatocellular CarcinomaRecruitingNCT06893887Not applicable
- Phase III Trial of Camrelizumab+Apatinib+Eribulin vs. Physician's Choice Chemotherapy in Advanced Triple-Negative Breast CancerRecruitingNCT06889688Phase 3
- Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular SubtypingNot yet recruitingNCT06881017Phase 2
- Phase II Study of PD-1 Inhibitor Combined With Apatinib and Mitotane in the Treatment of Advanced Adrenal Cortical CarcinomaRecruitingNCT06831175Phase 2
- PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric CancerRecruitingNCT06792162Phase 2
- A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung CancerNot yet recruitingNCT06786312Phase 2
- Adjuvant Adebrelimab Plus Apatinib After Chemoradiation in Limited-Stage Small Cell Lung CancerEnrolling by invitationNCT06773156Phase 2
- HS-10502 Combination Treatment in Patients With Advanced Solid TumorsRecruitingNCT06769425Phase 1
- Phase II Study of Adebrelimab, Chemotherapy, and Apatinib for Advanced Pulmonary Neuroendocrine TumorsNot yet recruitingNCT06764368Phase 2
- Metronomic Capecitabine with Camrelizumab and Apatinib Mesylate for Treatment of Advanced Pancreatic CancerNot yet recruitingNCT06759090Phase 2
- Adebrelimab Combined with Apatinib and Gemcitabine and Cisplatin (GP) First-line Treatment for Unresectable Biliary Tract CarcinomaRecruitingNCT06749730Phase 2
- Liposomal Irinotecan and Apatinib in ES-SCLCRecruitingNCT06749691Phase 2
- A Prospective, Randomized, Open, Phase II Clinical Study of Chidamide in Combination with Camrelizumab and Apatinib for Advanced Esophageal CancerNot yet recruitingNCT06745193Phase 2
- First-line Treatment of Advanced/unresectable DDLPSNot yet recruitingNCT06694324Phase 2
- A Study of Camrelizumab Plus Apatinib as Adjuvant Therapy in Patients With Hepatocellular Carcinoma at High Risk of Recurrence After Radical Resection or AblationNot yet recruitingNCT06546280Phase 2
- Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian CancerNot yet recruitingNCT06539091Phase 3
- SBRT Combined With Adbelimumab and Apatinib for Perioperative and Conversion Therapy of Hepatocellular CarcinomaNot yet recruitingNCT06538935Phase 2
- A Study of Microwave Ablation Combined With Immunotherapy ± Anti-angiogenic Drugs in the Treatment of Solid TumorsNot yet recruitingNCT06537505Phase 2
- A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung CancerRecruitingNCT06483282Phase 2
- Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingNCT06482086Phase 2
- Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung CancerRecruitingNCT06480864Not applicable
- Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionRecruitingNCT06454578Phase 2
- Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain MetastasisRecruitingNCT06418594Phase 2
- A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06415669Phase 2
- RC48 Combined With Adebrelimab, Apatinib and S-1 as Neoadjuvant Therapy in Locally Advanced Gastric CancerNot yet recruitingNCT06385873Phase 2
- Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCCRecruitingNCT06360042Phase 2
- Combination Immunotherapy of Adebrelimab With Apatinib and Tegafur, Gimeracil and Oteracil Potassium Capsules for Immune Rechallenge Therapy in Esophageal Squamous Cell CarcinomaRecruitingNCT06339619Phase 2
- A Multicenter Clinical Study of Apatinib Mesylate Combined With Doctor's Choice for Advanced Breast CancerNot yet recruitingNCT06339281Phase 2
- A Clinical Study of Adebrelimab Combined With Apatinib and Paclitaxel in Patients With Advanced Gastric Cancer.Not yet recruitingNCT06339216Phase 2
- Perioperative Treatment of Resectable Intrahepatic Cholangiocarcinoma With the Combination of Adebrelimab and Apatinib and HAICRecruitingNCT06296563Phase 2
- Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract CancerRecruitingNCT06280508Phase 2
- Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast CancerRecruitingNCT06255392Phase 3
- Rivoceranib in Patients With Metastatic Thymic Epithelial TumorNot yet recruitingNCT06200233Phase 2
- Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian CancerNot yet recruitingNCT06188455Phase 3
- A Study of Adebrelimab in Combination With Apatinib Gemcitabine and Cisplatin in Biliary Tract MalignanciesRecruitingNCT06181032Phase 1
- Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPiNot yet recruitingNCT06161272Phase 2
- Apatinib Combined With Camrelizumab in Treating Participants With Advanced ChordomaRecruitingNCT06140732Phase 2
- Tucidinostat Plus Apatinib for Advanced OsteosarcomaNot yet recruitingNCT06125171Phase 2
- Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance TreatmentNot yet recruitingNCT06081595Phase 2
- Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung CancerNot yet recruitingNCT05932264Phase 2
- Adebrelimab, Camrelizumab Plus Apatinib as First-line Therapy in Patients With Advanced Hepatocellular CarcinomaRecruitingNCT05924997Phase 1/2
- Rivoceranib Plus Paclitaxel in Patients With Gastrointestinal Stromal TumorRecruitingNCT05905887Phase 2
- Gemcitabine and Camrelizumab Plus Apatinib Versus Cisplatin in First-line Treatment of RM-NPCRecruitingNCT05854849Phase 3
- Surgical Conversion of Candonilimab (AK104) Plus Paclitaxel, S-1 and Apatinib for Unresectable Advanced G/GEJ CancerRecruitingNCT05853172Phase 2
- A Single-arm Clinical Study of HAIC Combined With Apatinib and Camrelizumab in the Treatment of Unresectable MTM HCCRecruitingNCT05839197Phase 2
- Camrelizumab in Combination With Apatinib and Temozolomide as First-line Treatment in Advanced Acral MelanomaRecruitingNCT05789043Phase 3
- Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GISTRecruitingNCT05751733Not applicable
- Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 Vs Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric CancerRecruitingNCT05699655Phase 2/3
- Advanced or Metastatic CholangiocarcinomaNot yet recruitingNCT05653817Not applicable
- SNF Platform Study of HR+/ HER2-advanced Breast CancerRecruitingNCT05594095Phase 2
- Fudan University Shanghai Cancer Center Breast Cancer Precision Platform Series Study- Neoadjuvant TherapyRecruitingNCT05582499Phase 2
- A Umbrella Study in R/R PTCL Guided by Molecular SubtypesRecruitingNCT05559008Phase 1/2
- A Phase II Trial of Camrelizumab in Combination With Apatinib for Neoadjuvant Treatment of Early-stage TNBC With a High Proportion of TILsRecruitingNCT05556200Phase 2
- Targeted or Chemotherapy Combined With Immunotherapy Versus Chemotherapy for PD-1 Inhibitor Refractory R/M NPCRecruitingNCT05549466Phase 2
- Clinical Study of Camrelizumab, Apatinib Mesylate and Nab-paclitaxel Combined With Oxplatin and S-1 in the Neoadjuvant Treatment of Locally Advanced Gastric Cancer With Different GenotypesNot yet recruitingNCT05524974Phase 2
- Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance TreatmentNot yet recruitingNCT05479487Phase 2
- Study of Camrelizumab Plus Apatinib and Chemotherapy as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC)RecruitingNCT05447702Phase 2
- mFOLFOX7 Plus Camrelizumab and Apatinib for Advanced HCCRecruitingNCT05412589Phase 2
- Study of Camrelizumab in Combination With Apatinib Mesylate Plus Albumin-bound Paclitaxel and Cisplatin as the First Line Treatment of Recurrent or Metastatic, UnresectableHead and Neck Squamous Cell CarcinomaNot yet recruitingNCT05189184Phase 2
- Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast CancerRecruitingNCT05019690Phase 1/2
- A Prospective, Phase II Trial Using ctDNA to Initiate Post-operation Boost Therapy After Adjuvant Chemotherapy in TNBCRecruitingNCT04803539Phase 2/3
- Apatinib Plus Camrelizumab Combined With Docetaxel and S1 in First-line Treatment for Metastatic Gastric CancerRecruitingNCT04781686Phase 2
- A Study of Camrelizumab Plus Apatinib as Consolidation Therapy in Non-Small Cell Lung Cancer Patients Treated With ChemoradiotherapyRecruitingNCT04749394Phase 2
- Camrelizumab With Apatinib as Neoadjuvant Therapy for Participants With Resectable Non-Small Cell Lung CancerNot yet recruitingNCT04506242Phase 2
- Apatinib in the Treatment of Recurrent Atypical/malignant Meningioma in AdultsRecruitingNCT04501705Not applicable
- Camrelizumab in Combination With Apatinib in Advanced ICC: A Single-arm Phase II StudyRecruitingNCT04454905Phase 2
- Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJCRecruitingNCT04342910Phase 3
- Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral MelanomaRecruitingNCT04331093Phase 2
- A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA MutationRecruitingNCT04296370Phase 3
- MASCT-I Combined With Apatinib and/or Camrelizumab in the Treatment of Bone and Soft Tissue SarcomaRecruitingNCT04074564Early Phase 1
- XELOX Plus Apatinib vs XELOX as Post-operative Chemotherapy in Locally Advanced Gastric Signet Ring CarcinomaNot yet recruitingNCT03355612Phase 3
- Apatinib as the First-Line Therapy in Elderly Locally Advanced or Metastatic Gastric CancerRecruitingNCT03219593Phase 2
- A Clinical Trial With Apatinib for Subjects With Refractory Malignant AscitesRecruitingNCT03020979Phase 2
- Neoadjuvant Therapy for Locally Advanced Colon CancerCompletedNCT04625803Phase 2Results posted
- A Study to Evaluate the Efficacy and Safety of Rivoceranib in Participants With Recurrent or Metastatic Adenoid Cystic Carcinoma (ACC)TerminatedNCT04119453Phase 2Results posted
- A Study to Evaluate SHR-1210 in Combination With Apatinib as First-Line Therapy in Patients With Advanced HCCCompletedNCT03764293Phase 3Results posted
- A Study of SHR-1210 Plus Apatinib in Patients With Soft Tissue SarcomaTerminatedNCT03711279Phase 2Results posted
- A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib in Patients With Advanced HCC(RESCUE)CompletedNCT03463876Phase 2Results posted
- SHR-1210 Combined With Apatinib in Treatment of ED-SCLC After Failure of First Line Standard TherapyCompletedNCT03417895Phase 2Results posted